Background: The latent HIV reservoir is the obstacle to a cure. HIV reactivation with histone deacetylase inhibitors (HDACis) such as SAHA (Vorinostat) in the presence of Highly Active Anti-Retroviral Therapy (HAART) is a candidate eradication strategy. However, the ability of SAHA to activate HIV in clinical trials appears limited. The primary action of SAHA thought to lead to HIV activation is the hyperacetylation of histones, but the off-target effects of this compound have not been well characterized. We have used an integrated systems biology approach (transcriptomics and proteomics) to reveal previously uncharacterized off-target effects of SAHA.
Methods: Primary CD4 T cells were isolated from 10 HIV seronegative donors and either treated with 1µM of SAHA for 24 hours or DMSO (Dimethyl Sulfoxide). Protein extracts from 4 donors were proteolyzed, labeled with iTRAQ 8-plex and characterized by two-dimensional liquid chromatography-mass spectrometry quantitative proteomics. Total RNA was isolated from the samples of 6 donors and subjected to transcriptomic analysis (Illumina HT12 v4 microarrays). Differentially expressed genes (DEGs) and proteins (DEPs), as well as differentially expressed phosphorylated (DPPs) and acetylated (DAPs) proteins were identified using Limma. Data integration was facilitated by merging data types and mapping the non-redundant set onto biological pathways, gene ontology terms, and protein interaction networks to characterize the off-target effects of SAHA.
Results: A total of 368 DEGs, 185 DEPs, 18 DPPs, and 4 DAPs (p-value < 0.05) were modulated by SAHA. Data integration suggested that SAHA modulates a number of off-target molecules that may enhance (e.g. AES, HSPA1A, KDM1A) or inhibit (e.g. BRD2, ETS1, HMGA1, INBKB, Lef-1) HIV reactivation. For example, HMGA1, which competes with Tat for TAR binding, was upregulated at the transcription and protein levels and acetylated as the result of SAHA treatment.
Conclusions: Integration of proteomic and transcriptomic data has revealed a number of off-target effects of SAHA that may hinder activation at the level of the HIV promoter. This sheds light on why combinations of PKC activators and HDACis are more effective than HDACis alone. Future functional genomics studies (e.g., siRNA knockdown) will determine the extent to which the off-target effects of SAHA inhibit viral activation so that they may be circumvented to help design more effective therapies.
Protein Interaction Network (PIN) showing differentially expressed genes (DEG), proteins (DEP), phosphorylated proteins (DPP) and acetylated proteins (DAP) in SAHA treated samples. The image was generated using MetaCore and Cytoscape.